ARTICLE | Top Story
NICE provisionally recommends Sovaldi
August 15, 2014 12:24 AM UTC
The U.K.'s NICE provisionally recommended Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) for chronic HCV infection in its second (see BioCentury Extra, June 16). ...